Develop drugs using the blood of new coronal pneumonia rehabilitation recipients! Lilly has a partnership with Ab Cellera.

Within a week of receiving the first blood samples from COVID-19 recovered U.S. patients, AbCellera screened more than 5 million immune cells to find those that could produce functional antibodies that help patients neutralize the virus and recover from the disease.
through this effort, AbCellera has identified more than 500 unique all-human antibody sequences, the largest reported anti-SARS-CoV-2 antibody group to date.
the next step is to screen these antibodies to identify the most effective antibodies for neutralizing SARS-CoV-2.
many of these antibodies will be expressed in collaboration with partners at the National Institutes of Allergy and Infectious Diseases Research (VRC) affiliated with the National Institutes of Health (NIAID) and will test the ability of these antibodies to neutralize the new coronavirus SARS-CoV-2 after an agreement with NIAID.
under the terms of the agreement, AbCellera and Lilly are committed to sharing the initial development costs of the product equally, after which Lilly will be responsible for all further development, manufacturing and distribution.
if successful, Lilly is prepared to work with regulators around the world to treat patients.
AbCellera is a private company that works together to identify and develop the next generation of therapeutic antibodies.
AbCellera's single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery with a unique combination of technologies, including proprietary immunity, microflow control, high-throughput imaging, genomics, deep computing, artificial intelligence, and laboratory automation.
ultra-deep screening of individual B cells results in an unprecedented natural immune response that enables the rapid separation of large and diverse large quantities of high-quality pilot antibodies from any species, including humans.
natural immune response produces billions of potential antibodies and is the best source for finding novel antibody therapies.
, with its drug discovery platform capable of searching and automatically analyzing the immune system to provide best-of-the-kind antibodies, AbCellera was recently named fast company's top 2020 top 50 list of the world's most innovative companies. Dr Carl Hansen, ceo of
AbCellera, said: "AbCellera's platform delivers the largest anti-SAR-CoV-2 antibody group in the world to date at an unprecedented rate.
over an 11-day period, we found hundreds of antibodies to the SARS-CoV-2 virus, collaborated with global virology experts on functional testing, and signed a development agreement with one of the world's leading biopharmaceutical companies.
we're impressed with Lilly's speed and agility in meeting global challenges.
our team work together to provide a response to prevent an outbreak. "With the dramatic increase in the number of new cases of coronavirus pneumonia (COVID-19) worldwide, doctors and patients are seeking a therapeutic intervention to accelerate patient recovery or prevent disease," said Daniel Skovronsky, M.D., Chief Scientific Officer of Lilly, Lilly Research Laboratory,
.
Lilly is committed to playing our role in the global outbreak and bringing innovation to patients.
we worked with AbCellera because we were impressed with the speed and quality of their work.
we're working to create a potential treatment to help patients as quickly as possible.
While a new therapeutic antibody program usually takes years to get into the clinic, our goal for AbCellera is to test patients for potential new therapies within the next four months.
"